224 results about "Intramuscular injection" patented technology

The present application provides an RNA encoding a varicella-zoster (VZV) glycoprotein E (gE) or a variant thereof, the RNA comprising a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence represented by any one of SEQ ID NO: 11-18. The eight mRNAs provided by the invention can translate in cells, the expression level of the generated VZV gE protein is high, and the mRNAs can induce a mouse to generate a high-titer gE specific IgG antibody in a manner of intramuscular injection into the body of the mouse through a preparation formed by encapsulating the lipidosome nanoparticles.

The present disclosure relates to the expression of recombinant viral antigens using transgenic fungi. Compositions, production and administration of vaccines comprising those viral antigens are also disclosed. In some embodiments, these viral antigens can be used to formulate vaccines against Newcastle disease. These vaccines may be administered, for example, by intramuscular injection.

The invention relates to a method for stimulating an immune response by intramuscular injection of an artificial nucleic acid molecule comprising an open reading frame encoding an antigen and a 3′-UTR comprising at least two poly(A) sequences. The method may yield an increased immune response to the antigen or an increased neutralizing antibody response to the antigen.

The invention belongs to the technical field of aquaculture, and relates to a thioacetamide-induced procambarus clarkii hepatopancreas injury model construction and evaluation method and application thereof, and the method comprises the following steps: selecting healthy and temporarily cultured procambarus clarkii with the weight of 10.0 + / -1.45 g as an object for establishing the hepatopancreas injury model; fasting the procambarus clarkii for 12 hours, and then giving a thioacetamide solution, wherein the application dosage is 0.4-0.8 mg / g body weight; the thioacetamide is a thioacetamide solution which is prepared from a 0.9 wt% NaCl solution and has the concentration of 40 to 80 mg / mL; the mode of administration of the thioacetamide solution is intramuscular injection. The TAA is applied to construction of the hepatopancreas injury model of the procambarus clarkia for the first time, individual death is not induced in the model construction process, and an ideal experimental model capable of researching pathogenesis of hepatopancreas diseases and screening related therapeutic drugs is obtained. The method has the advantages of being short in period, low in cost, easy to operate, good in repeatability and the like.

The invention particularly relates to a diphtheria toxin antigen modified by fatty acid and application thereof, and belongs to the field of biological medicine, in the diphtheria toxin antigen modified by fatty acid, the fatty acid modification comprises N-terminal cysteine (Cys) modified by fatty acid, the N-terminal Cys modified by fatty acid is characterized in that sulfydryl containing Cys is modified by diacylglycerol and / or alpha amino is modified by fatty acyl. Compared with the existing diphtheria toxin protein antigen, the fatty acid modified diphtheria toxin antigen not only has faster induction and higher immune protection effect than the conventional intramuscular injection induction of the existing diphtheria toxin antigen, but also can induce respiratory tract mucosa immunity, and provides a basis for blocking diphtheria infection and diffusion propagation and providing a vaccine for immunoprophylaxis.

The invention relates to a method for editing target genes of prawn filial generations by exopalaemon carinicauda or vannabine and application of the method. Based on the gonad development and reproduction characteristics of shrimps and crabs, Cas9 RNP (a mixture formed by mixing sgRNA and Cas9 ribonucleoprotein) is directly injected into bodies of exopalaemon carinicauda or litopenaeus vannamei with developed ovaries in an intramuscular injection manner. The used sgRNA is a guide RNA (Ribonucleic Acid), namely EcIAG-gRNA or LvIAG-gRNA, which is designed on the basis of an IAG gene (EcIAG or LvIAG) of exopalaemon carinicauda or litopenaeus vannamei. Different gRNAs and Cas9 proteins are respectively mixed and then injected into an exopalaemon carinicauda or litopenaeus vannamei parent body through intramuscular injection, Cas9 RNP can enter an ovary along with blood circulation and enter an oocyte along with development of the ovary, editing of a target gene on a genome is realized, and after the edited oocyte develops into an ovum, a progeny edited mutant is formed through fertilization. The method can also be used for delivering other biological macromolecular substances to oocytes of decapod crustacean such as exopalaemon carinicauda or litopenaeus vannamei.

The invention discloses mannheimia haemolytica outer membrane vesicles as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The OMV is separated from Mh-5 strain culture supernatant through tangential flow ultrafiltration combined with an ultracentrifugation technology, and animal experiments prove that a high-level IgG / IgM antibody can be induced by intramuscular injection of 50 micrograms per mouse, expression of inflammatory factors such as IL-6 and TNF-alpha of the spleen is remarkably improved, the protection rate after challenge reaches 85.7%, and pathological damage is remarkably lighter than that of an inactivated vaccine group. According to the scheme provided by the invention, the problems of insufficient serotype coverage and antibiotic resistance in the prior art are solved, and a new strategy is provided for prevention and control of mannheimia haemolytica.

The invention discloses riemerella anatipestifer and application of the riemerella anatipestifer in an egg yolk antibody. The riemerella anatipestifer is named as BRA22A011, and the preservation number of the riemerella anatipestifer is CGMCC (China General Microbiological Culture Collection Center) No.45887. The invention also discloses an inactivated vaccine, wherein the antigen in the inactivated vaccine contains the inactivated riemerella anatipestifer BRA22A011. The invention further discloses an egg yolk antibody, and the egg yolk antibody is prepared by using the riemerella anatipestifer BRA22A011 as an antigen. The use mode of the egg yolk antibody is intramuscular injection inoculation, and the injection dosage is 0.5 mL. The riemerella anatipestifer BRA22A011 has high pathogenicity and strong immunogenicity, and the egg yolk antibody prepared from the riemerella anatipestifer BRA22A011 can replace antibiotics and vaccines, is safe, free of residues, free of drug resistance and environment-friendly, and has a good prospect in clinical application of preventing and treating infectious serositis of ducks. The riemerella anatipestifer BRA22A011 and the Escherichia coli BE-20261 are adopted for preparing the egg yolk antibody together, and the prevention and treatment effects of the egg yolk antibody are more obvious.

The invention relates to a batch production method capable of optimizing the sow delivery induction process and improving the delivery concentration ratio. Comprising the following steps: S1, determining an expected date of confinement of a sow; s2, injecting cloprostenol sodium into the pudendum of the sow in the morning one day before the expected date of confinement; s3, performing intramuscular injection of carbetocin for the sows in the morning of the expected date of confinement. According to the method, potential adverse effects of childbirth induction are deeply studied, the optimal time and dosage for combined use of cloprostenol sodium and beioxytocin are determined, childbirth induction for batch production of sows is optimized, the childbirth time of the sows is concentrated in the working time of a pig farm, the labor efficiency is improved, and the labor intensity is reduced.

The invention relates to a method of treating or preventing a disease or condition comprising administering a therapeutically effective amount of a psychedelic compound to a patient by intramuscular injection. Uses, formulations and kits are also described.

The invention relates to the technical field of biological medicine, and discloses a nanoparticle vaccine based on an HER2 target spot and application of the nanoparticle vaccine, and the nanoparticle vaccine based on the HER2 target spot comprises an HER-2 gene related antigen sequence HER2 and hepatitis B core virus-like particle nanoparticles HBc VLPs; the amino acid sequences of the gene are respectively shown as SEQ ID No. 1 and SEQ ID No. 2. According to the invention, hepatitis B core virus-like particles are modified by using B cell epitopes of HER2 targets, and the nanoparticle tumor vaccine suitable for intramuscular injection is prepared. The vaccine aims at reducing clinical safety risks and reducing immune tolerance and toxic and side effects caused by long-term use of monoclonal antibody drugs. Through an active immunization mode, an organism can continuously generate an anti-HER2 specific antibody, and clinical guidance is provided for research and development of therapeutic general tumor vaccines.

The invention relates to the technical field of animal husbandry, in particular to a synchronous oestrus-timing insemination method suitable for cattle, which comprises the following steps: firstly, performing intramuscular injection of PG (cloprostenol sodium) at different time points after calving to promote uterine recovery and luteolysis and lay a synchronous oestrus foundation; the method comprises the key steps that GnRH (gonadotropin release hormone) is given through intramuscular injection on the 43rd day, the 53rd day, the 60th day and the 69th day, pituitary is promoted to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), collection and screening of follicles are guided, follicle maturation is promoted, the oestrus uncovering rate and the oestrus conception rate are increased, a melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day, and the melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day. The synthesis of ovarian hormones is promoted by regulating the hypothalamus-pituitary-gonad axis, the secretion of follicle cell factors and maturation promoting factors is promoted, the development of granular cells is promoted, and the maturation of oocytes is promoted. According to the method, the pregnancy rate of a double-synchronization-timing insemination scheme which is most widely used in a large-scale dairy cow breeding pasture at present can be remarkably increased, and feasible technical support is provided for success of increasing the breeding efficiency of cows.

The invention discloses a timed insemination method for improving the pregnancy rate and the lambing rate of sheep, and belongs to the technical field of livestock breeding. In order to solve the problem that the pregnancy rate of existing sheep is unstable during regular insemination, the method comprises the steps that a progesterone sponge suppository is embedded in the vagina of a healthy and reproductive ewe on the 0th day, and meanwhile 25 g of luteinizing hormone is injected in an intramuscular mode to release hormone A3; removing the thrombus on the 12th day, and performing intramuscular injection of 400IU of pregnant mare serum gonadotropin at the same time; and after the suppository is removed, insemination is carried out on the cervix orifice of the ewe with ram semen diluted at the ratio of 1: (5-8) in 52h and 64h respectively. According to the method, ovarian activities of the ewes are regulated and controlled, the estrus synchronism and the ovulation rate are improved, tests show that the pregnancy rate reaches 81.6%, the lambing rate is 1.14, compared with a conventional method, the pregnancy rate and the lambing rate of the sheep are remarkably improved, and development of the sheep industry is promoted.

The invention discloses an electric local anesthetic injection device and relates to the technical field of medical instruments, a fixed sliding rail is mounted at the top of a rotating flat head, fixed sliding blocks are slidably mounted at two ends in the fixed sliding rail, a bidirectional screw is rotatably mounted in the fixed sliding rail, a clamping plate is connected to the top of each fixed sliding block, and a handle is clamped in the middle of the clamping plate; a limiting sliding groove is formed in one end of the top of the handle, a fixing frame is installed at the other end of the top of the handle, a heat preservation electric heating plate is installed at the bottom of the fixing frame, and an injector is placed at the top of the fixing frame. The labor intensity of anesthetists is greatly reduced, when intramuscular injection is carried out on a patient, a needle head can be rapidly positioned, injection is convenient and fast, electric quantitative injection can also be carried out, two operation modes are adopted, and the anesthetic syringe is suitable for being used under different conditions, more comprehensive and reasonable in operation and suitable for being used and popularized.

The invention relates to medicine, in particular to gerontology and therapy and can be used for treating sarcopenia in elderly patients.Summary of the invention consists in alternating for 1…2 days the intravenous administration of ozonized 0.9% NaCl solution and major autohemotherapy, namely 500 mL of a 0.9% NaCl solution ozonized with an ozone-oxygen mixture, with an ozone concentration of 5…10 µg / mL, are administered, and major autohemotherapy consists in collecting 300…400 mL of venous blood from the patient, which is ozonized, with an ozone concentration of 15 µg / mL and transfused to the patient, the treatment course includes 8…10 consecutive procedures, then it is extended with minor autohemotherapy, which consists in collecting 5…10 mL of venous blood, which is ozonized, with an ozone concentration of 15 µg / mL and administered intramuscularly every 10th day of alternation and includes 3 consecutive procedures, and the ozonized 0.9% NaCl solution is administered for up to 6…8 weeks.

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

This invention provides a modified BoNT / A for treating facial wrinkles, wherein the modified BoNT / A is administered via intramuscular injection at multiple sites on an individual's face, wherein the modified BoNT / A is administered at a unit dose of greater than 1754 pg or greater than 8000 pg per site, wherein the multiple sites are selected from: up to two sites on the corrugator supercilii muscle and one site on the depressor supercilii muscle for treating glabellar lines; up to five sites on the frontalis muscle for treating forehead wrinkles; and up to three sites on the orbicularis oculi muscle for treating lateral canthal wrinkles, wherein the total dose of modified BoNT / A administered during treatment is up to 264,000 pg (and optionally greater than 88,000 pg), and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N The structure domain), and the BoNT / B receptor binding domain (H C (structural domain).

The present invention relates to aqueous saline solutions comprising dantrolene and optionally at least one additional active ingredient, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic purposes. The solutions can be administered in any suitable manner, but have the advantage of being particularly well-suited for intramuscular injection.

Compounds comprising antiviral prodrugs, and pharmaceutical formulations comprising the compounds, which can be orally bioavailable or formulated for intramuscular injection. Methods for making compounds such as antiviral prodrugs. Methods for treating coronavirus and other RNA viral infections in mammals. Methods for producing pharmaceutical triphosphates.

The utility model relates to the technical field of syringe needle limiting parts, and discloses a stable muscle syringe needle limiting mechanism which comprises a supporting sleeve, a supporting plate and a syringe needle assembly, the supporting plate is arranged at the bottom of the supporting sleeve, and the syringe needle assembly is located on the inner side of the supporting sleeve and penetrates to the bottom of the supporting plate. An adjusting assembly is arranged on the outer side of the supporting sleeve, a limiting supporting assembly which is arranged on the outer side of the syringe needle assembly in a sleeving mode and fixedly connected with the adjusting assembly is arranged in the supporting sleeve, and a supporting movable assembly is arranged at the bottom of the supporting plate. According to the stable muscle syringe needle limiting mechanism, medical staff are allowed to adjust and lock the insertion depth of the syringe needle, the accuracy and safety of injection are improved, the stable muscle syringe needle limiting mechanism can adapt to syringe needles of different lengths, the supporting stability of the syringe needle limiting mechanism is improved, use convenience is improved, and the stable muscle syringe needle limiting mechanism is worthy of popularization and application. And the use of a user is facilitated.

The utility model belongs to the field of medical instruments, and particularly relates to a fulvestrant intramuscular injection positioning ruler which comprises a long fixed ruler, two short shifting rulers and two arc-shaped pieces, and the two short shifting rulers are located on the two sides of the long fixed ruler respectively and rotationally connected with the long fixed ruler; the two arc-shaped pieces are symmetrically distributed on the two sides of the long fixed ruler, one side of each arc-shaped piece is fixedly connected with the long fixed ruler, the other side of each arc-shaped piece is fixedly connected with the short shifting ruler, an arc-shaped notch is formed in the inner side of each arc-shaped piece, and a plurality of positioning holes are formed in each arc-shaped piece. The fulvestrant injection device is directly aligned with the highest point of iliac spine and the peak of hip fissure of a human body through the positioning rule in one step, compared with operation modes such as a cross method and a line connection method, the time for manual searching and positioning is saved, meanwhile, injection of fulvestrant is completed in the positioning hole, and the injection efficiency is improved. And injection errors and complications caused by non-professional operation methods, inaccurate manual positioning, repeated part injection and the like are solved, so that the injection pain of a patient is reduced, and the treatment compliance and the life quality are improved.

An embodiment of the present invention provides a biocompatible, thermosensitive hydrogel composition for subcutaneous or intramuscular injection, the hydrogel comprising a poloxamer, such as poloxamer 338, poloxamer 188, or poloxamer 407, or a mixture thereof, and the composition includes a therapeutic protein or antigen embedded in the composition for sustained release.

The invention relates to a liquid aqueous formulation of pyronaridine for use in medical treatment, said liquid aqueous formulation comprising at least 70 wt.% water and at least 40 µmol / ml of dissolved pyronaridine, having a pH in the range of 2.5 to 5.8 and being characterised in that the ratio of the osmolality of the formulation (in Osm / kg) to the pyronaridine concentration of the formulation (in mmol / mL) is less than 2.0. The invention also relates to a sterile liquid aqueous formulation comprising at least 70 wt.% water and at least 40 µmol / ml of dissolved pyronaridine, having an osmolality in the range of 0.15 to 0.60 Osm / kg, a pH in the range of 2.5 to 5.8 and being characterised in that the ratio of the osmolality of the formulation (in Osm / kg) to the pyronaridine concentration of the formulation (in mmol / mL) is less than 2.0. The concentrated aqueous pyronaridine formulation of the present invention is perfectly suited for intramuscular administration, but can also suitably be administered subcutaneously, intranasally, orally, intraperitonially or intravenously.

The present invention relates to aqueous compositions comprising dantrolene and optionally also at least one additional active principle, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic / cosmetic purposes. The compositions can be administered in any suitable way but are advantageous in that they are particularly well adapted to intramuscular injection, subcutaneous injection and / or intradermal injection.

The invention relates to an external ointment for wound treatment, which is mainly used for treating burns and scalds and also used for treating skin soft tissue injury caused by other reasons such as acid-base corrosion, skin soft tissue injury and the like. The traditional Chinese medicine belongs to a wet bandaging therapy, and has the advantages of good effect, stable medicine property, no toxic or side effect, simplicity, feasibility, low price, no injury surface exposure, mobility of a patient during treatment, no obvious scar formation without skin grafting, easy acceptance by the patient and the like if the medicine needs to be carefully changed. Intravenous injection or intramuscular injection or oral administration of a critical patient such as replenishment liquid acid-base balance anti-infection and the like needs to be carried out simultaneously, so that the aim of curing can be achieved.

The invention discloses a dexketoprofen trometamol nasal spray and a preparation method thereof, a buffering agent is used as a stabilizer, and the dexketoprofen trometamol nasal spray which is good in stability, small in irritation, convenient, rapid in effect taking and extremely small in side effect is provided, so that the medication compliance of patients and the convenience of clinical medication are improved; after being administrated, the nasal spray can be quickly absorbed through nasal mucosa, the absorption speed is equivalent to that of intramuscular injection, the nasal spray can quickly reach the peak concentration as intramuscular injection, and the curative effect can be quickly exerted; the preparation has the advantages of no first-pass effect during nasal mucosa administration, high bioavailability and rapid absorption, is suitable for self-rapid analgesia, and is stable in process and suitable for large-scale production.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

The invention relates to an artificial intelligence-based decision support method for determining the sciatic nerve prior to intramuscular injection and enabling safe injection.

The invention belongs to the technical field of pharmaceutical preparations and preparation thereof, and discloses a sustained-release type chlorsulfuron nano preparation, and every 100 g of the preparation comprises the following components by weight: 0.1 to 5.0 g of chlorsulfuron, 0.5 to 3.5 g of myristyl alcohol, 3.0 to 9.0 g of fir oil, 1.0 to 5.0 g of ethyl acetate, 3.0 to 6.0 g of polyoxyethylene (2) oleyl alcohol ether, 8.0 to 20.0 g of tween-20, 1.0 to 2.0 g of xylitol, 0.01 to 0.1 g of triethanolamine, and the balance of water for injection. After intramuscular injection, the medicine is slowly released in a tissue local part, a long-acting effect can be achieved, the administration frequency is reduced, and the animal stress reaction is reduced. And meanwhile, the particle size of the medicine is distributed at a nanometer level, so that the bioavailability is greatly improved. The invention further discloses a preparation method, and the preparation method does not need special equipment, can be converted in a common workshop, and has a wide market prospect.

The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg / ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.